Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31245696 | 0.94 | KDM4E (0.42) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20688889 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL26098304 | 0.89 | PTPN1 (0.49) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21887375 | 0.84 | KDM4E (0.42) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL22092637 | 0.82 | KDM4E (0.41) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21887777 | 0.82 | MAPT (0.44) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25070256 | 0.81 | KDM4E (0.51) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20689640 | 0.81 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30349310 | 0.81 | CCNA2 (0.54) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21887781 | 0.81 | NPSR1 (0.43) | KDM4EHSD17B10ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692096-A1 | MACROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| WO-2024199479-A1 | MACROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12060356-B2 | 7 (methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives | ELI LILLY AND COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-11891400-B2 | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus | ELI LILLY AND COMPANY (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3894412-B1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | LILLY CO ELI (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3849981-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | LILLY CO ELI (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3849981-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | LILLY CO ELI (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220024933-A1 | 7 (METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY | 2022-01-27 | — | — | US | disclosed |
| US-20220024933-A1 | 7 (METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY | 2022-01-27 | — | — | US | disclosed |
| EP-3849981-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY | 2021-06-24 | — | — | US | disclosed |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY | 2021-06-24 | — | — | US | disclosed |
| WO-2020123225-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020055636-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020055636-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060356-B2 | 7 (methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives | SSB, TLR7, TPMT | KDM4E 802/4885HSD17B10 4323/4885ALDH1A1 1636/4885 |
| US-20240335443-A1 | IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS | TYK2, PTK2B, JAK1 | KDM4E 901/4885HSD17B10 4388/4885ALDH1A1 4073/4885 |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | KDM4E 108/4885HSD17B10 2517/4885ALDH1A1 4504/4885 |
| US-11891400-B2 | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus | SSB, TPMT, SPHK1 | KDM4E 129/4885HSD17B10 4709/4885ALDH1A1 2192/4885 |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, TPMT, SPHK1 | KDM4E 129/4885HSD17B10 4709/4885ALDH1A1 2192/4885 |
| US-20220024933-A1 | 7 (METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | SSB, TLR7, TPMT | KDM4E 802/4885HSD17B10 4323/4885ALDH1A1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.